Skip to content

Chuankezhi injection treatment of children with asthma multicenter study

Chuankezhi injection treatment of children with asthma multicenter study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13003212
Enrollment
Unknown
Registered
2013-04-26
Start date
2013-05-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Interventions

Treatment group:basical treatment plus ChuanKeZhi injection
control group:basical treatment plus ChuanKeZhi injection

Sponsors

Guangzhou Women and Children's Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
4 Years to 14 Years

Inclusion criteria

Inclusion criteria: 1.Aged 4 to 14 years; 2. Meet diagnostic criteria of childhood asthma diagnostic guidelines and TCM pediatric asthma dialectical type; 3. In line with persistent asthma in children in mild or severe acute asthma exacerbation; 4. parents or legal guardians understood and signed an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Children combined can cause asthma or breathing difficulties other diseases that may affect the efficacy determine; 2. The merger heart, brain, liver, kidney and hematopoietic system in patients with primary disease; 3. Can not use the test Syndrome condition explanation serum creatinine (Cr), blood urea nitrogen (BUN) and glutamic-pyruvic transaminase (GPT or ALT) increased urine protein ++ or urine red blood cells++; 4. Allergic to the drug used in this study; 5. Participated or are participating in clinical trials of other drugs in the past three months; 6. Children or guardian cognitive functional limitations or other reasons not be completed properly fill out the scale; 8. According to the doctor's judgment, likely to cause lost to follow.

Design outcomes

Primary

MeasureTime frame
Acute exacerbation of symptoms score and complete;reliever use;Asthma control during the follow-up perio;

Secondary

MeasureTime frame
C-ACT /ACT;PedQL3.0 / PAQLQ;Inhaled steroids dose;Blood routine tests;Liver function;Kidney function;Total serum IgE;Specific IgE;Sputum pathogenic examination;

Countries

china

Contacts

Public ContactDeng li
drdengli@126.com+86 13711220382

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026